- Sections
- C - Chimiemétallurgie
- C07D - Composés hétérocycliques
- C07D 211/88 - Atomes d'oxygène liés en positions 2 et 6, p. ex. glutarimide
Détention brevets de la classe C07D 211/88
Brevets de cette classe: 137
Historique des publications depuis 10 ans
|
8
|
10
|
16
|
9
|
10
|
5
|
9
|
9
|
12
|
9
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Cv6 Therapeutics (NI) Limited | 32 |
16 |
| C4 Theraprutics, Inc. | 56 |
10 |
| University of Southern California | 2109 |
6 |
| Takeda Pharmaceutical Company Limited | 2708 |
5 |
| Obschestvo S Ogranichennoi Otvetstvennostiyu "pharmenterprises" | 31 |
4 |
| Rhodia Operations | 1581 |
4 |
| Kymera Therapeutics, Inc. | 227 |
4 |
| Shuttle Pharmaceuticals, Inc. | 17 |
4 |
| California Institute of Technology | 3969 |
3 |
| Zhejiang Jiuzhou Pharmaceutical Co., Ltd. | 70 |
3 |
| Bioventures, LLC | 223 |
3 |
| Arvinas Operations, Inc. | 225 |
3 |
| Mitsui Chemicals Agro, Inc. | 89 |
2 |
| Council of Scientific & Industrial Research | 1423 |
2 |
| Eli Lilly and Company | 3825 |
2 |
| Institute of Zoology, Chinese Academy of Sciences | 108 |
2 |
| Keio University | 1091 |
2 |
| Korea Research Institute of Chemical Technology | 1380 |
2 |
| Mirati Therapeutics, Inc. | 247 |
2 |
| NHWA Pharma. Corporation | 52 |
2 |
| Autres propriétaires | 56 |